Patrick Phelan1, Heather E Merry1, Billanna Hwang2, Michael S Mulligan3. 1. Department of Surgery, University of Washington School of Medicine, Seattle, Wash. 2. Department of Surgery, University of Washington School of Medicine, Seattle, Wash; Center for Lung Biology, University of Washington, Seattle, Wash. Electronic address: bhwang@u.washington.edu. 3. Department of Surgery, University of Washington School of Medicine, Seattle, Wash; Center for Lung Biology, University of Washington, Seattle, Wash.
Abstract
OBJECTIVE: The requirement for toll-like receptors (TLRs) in lung ischemia reperfusion injury (LIRI) has been demonstrated but not fully characterized. Previously, we reported that TLR-4 is required by alveolar macrophages but not pulmonary endothelial or epithelial cells for development of LIRI. Additionally, we demonstrated differential patterns of mitogen-activated protein kinase (MAPK) activation and cytokine release in these cell types during LIRI. Here, we sought to determine whether these differences in activation responses are related to cell-specific TLR activation requirements. METHODS: Primary cultures of alveolar macrophages, pulmonary endothelial, and immortalized epithelial cells were pretreated with TLR-2 or TLR-4 short interference RNA (ribonucleic acid) before hypoxia and reoxygenation. Cell lysates and media were analyzed for receptor knockdown, MAPK activation, and cytokine production. Rats were pretreated with TLR-2 or TLR-4 short interference RNA before lung ischemia reperfusion and changes in lung vascular permeability were assessed. RESULTS: Knockdown of TLR-2 in alveolar macrophages did not affect MAPK phosphorylation or cytokine secretion. Conversely, TLR-2 knockdown in pulmonary endothelial and epithelial cells demonstrated significant reductions in extracellular signal-regulated kinase 1/2 activation and cytokine secretion. The lung permeability index in LIRI was decreased by TLR-4 but not TLR-2. CONCLUSIONS: Differential TLR signaling and MAPK activation in response to LIRI seem to be cell specific. Short interference RNA provides an outstanding tool for examination of the underlying mechanism. Published by Elsevier Inc.
OBJECTIVE: The requirement for toll-like receptors (TLRs) in lung ischemia reperfusion injury (LIRI) has been demonstrated but not fully characterized. Previously, we reported that TLR-4 is required by alveolar macrophages but not pulmonary endothelial or epithelial cells for development of LIRI. Additionally, we demonstrated differential patterns of mitogen-activated protein kinase (MAPK) activation and cytokine release in these cell types during LIRI. Here, we sought to determine whether these differences in activation responses are related to cell-specific TLR activation requirements. METHODS: Primary cultures of alveolar macrophages, pulmonary endothelial, and immortalized epithelial cells were pretreated with TLR-2 or TLR-4 short interference RNA (ribonucleic acid) before hypoxia and reoxygenation. Cell lysates and media were analyzed for receptor knockdown, MAPK activation, and cytokine production. Rats were pretreated with TLR-2 or TLR-4 short interference RNA before lung ischemia reperfusion and changes in lung vascular permeability were assessed. RESULTS: Knockdown of TLR-2 in alveolar macrophages did not affect MAPK phosphorylation or cytokine secretion. Conversely, TLR-2 knockdown in pulmonary endothelial and epithelial cells demonstrated significant reductions in extracellular signal-regulated kinase 1/2 activation and cytokine secretion. The lung permeability index in LIRI was decreased by TLR-4 but not TLR-2. CONCLUSIONS: Differential TLR signaling and MAPK activation in response to LIRI seem to be cell specific. Short interference RNA provides an outstanding tool for examination of the underlying mechanism. Published by Elsevier Inc.
Authors: Michael T McManus; Brian B Haines; Christopher P Dillon; Charles E Whitehurst; Luk van Parijs; Jianzhu Chen; Phillip A Sharp Journal: J Immunol Date: 2002-11-15 Impact factor: 5.422
Authors: Luis F Angel; Deborah J Levine; Marcos I Restrepo; Scott Johnson; Edward Sako; Andrea Carpenter; John Calhoon; John E Cornell; Sandra G Adams; Gary B Chisholm; Joe Nespral; Ann Roberson; Stephanie M Levine Journal: Am J Respir Crit Care Med Date: 2006-06-23 Impact factor: 21.405
Authors: Steven M Fiser; Curtis G Tribble; Stewart M Long; Aditya K Kaza; John A Kern; David R Jones; Mark K Robbins; Irving L Kron Journal: Ann Thorac Surg Date: 2002-04 Impact factor: 4.330
Authors: R C King; O A Binns; F Rodriguez; R C Kanithanon; T M Daniel; W D Spotnitz; C G Tribble; I L Kron Journal: Ann Thorac Surg Date: 2000-06 Impact factor: 4.330
Authors: Babu V Naidu; Baiya Krishnadasan; Karen Byrne; Angie L Farr; Matthew Rosengart; Edward D Verrier; Michael S Mulligan Journal: Ann Thorac Surg Date: 2002-09 Impact factor: 4.330
Authors: Alana A Shigeoka; Todd D Holscher; Andrew J King; Frank W Hall; William B Kiosses; Peter S Tobias; Nigel Mackman; Dianne B McKay Journal: J Immunol Date: 2007-05-15 Impact factor: 5.422
Authors: Patrick S Wolf; Heather E Merry; Alexander S Farivar; Anton S McCourtie; Michael S Mulligan Journal: J Thorac Cardiovasc Surg Date: 2008-02-14 Impact factor: 5.209
Authors: Vibha N Lama; John A Belperio; Jason D Christie; Souheil El-Chemaly; Michael C Fishbein; Andrew E Gelman; Wayne W Hancock; Shaf Keshavjee; Daniel Kreisel; Victor E Laubach; Mark R Looney; John F McDyer; Thalachallour Mohanakumar; Rebecca A Shilling; Angela Panoskaltsis-Mortari; David S Wilkes; Jerry P Eu; Mark R Nicolls Journal: JCI Insight Date: 2017-05-04
Authors: J L Carvalho; A Britto; A P Ligeiro de Oliveira; H Castro-Faria-Neto; R Albertini; E Anatriello; F Aimbire Journal: Lasers Med Sci Date: 2016-12-06 Impact factor: 3.161
Authors: Andrew E Gelman; Andrew J Fisher; Howard J Huang; Maher A Baz; Ciara M Shaver; Thomas M Egan; Micheal S Mulligan Journal: J Heart Lung Transplant Date: 2017-07-24 Impact factor: 10.247
Authors: Tara Talaie; Laura DiChiacchio; Nikhil K Prasad; Chetan Pasrija; Walker Julliard; David J Kaczorowski; Yunge Zhao; Christine L Lau Journal: Transplant Direct Date: 2021-01-07
Authors: Jan Van Slambrouck; Dirk Van Raemdonck; Robin Vos; Cedric Vanluyten; Arno Vanstapel; Elena Prisciandaro; Lynn Willems; Michaela Orlitová; Janne Kaes; Xin Jin; Yanina Jansen; Geert M Verleden; Arne P Neyrinck; Bart M Vanaudenaerde; Laurens J Ceulemans Journal: Cells Date: 2022-02-21 Impact factor: 6.600